Management indicated plans to provide both regulatory and clinical trial updates on blarcamesine for indications beyond Alzheimer’s, including Parkinson’s disease, Rett syndrome, and Fragile X.
Earnings Call Insights: Anavex Life Sciences Corp. (AVXL) Q4 2025 Management indicated plans to provide both regulatory and clinical trial updates on blarcamesine for indications beyond Alzheimer’s, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results